Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jemermed.2025.03.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply to "Letter to Editor by Dr. Steckner Regarding 'Induction of Extremely Severe Nausea via Vestibular Activation on a 7 Tesla MRI Scanner' by Fagan et al.".
J Magn Reson Imaging
August 2025
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
In Reply: Predictors of Hydrocephalus Risk After Stereotactic Radiosurgery for Vestibular Schwannomas: Utility of the Evans Index.
Neurosurgery
July 2025
Department of Neurosurgery, New York University Langone Medical Center, New York , New York , USA.
Reply to Vestibular Migraine or Transitory Ischemic Attack in the Posterior Circulation-How to Differentiate.
J Emerg Med
September 2025
Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA; Department of Emergency Medicine, Harvard Medical School, Boston, MA.
World-wide survey on the treatment of peripheral vestibular disorders.
Front Neurol
February 2025
German Center for Vertigo and Balance Disorders, LMU University Hospital, LMU Munich, Munich, Germany.
Objective: The aim of this world-wide survey was to evaluate the currently applied treatment options for the six most frequent peripheral vestibular disorders: benign paroxysmal positional vertigo (BPPV), acute unilateral vestibulopathy (AUVP)/vestibular neuritis, Menière's disease (MD), bilateral vestibulopathy (BVP), vestibular paroxysmia (VP) and superior canal dehiscence syndrome (SCDS).
Background: For the therapy of vestibular disorders, there are four treatment options: vestibular physical therapy (canalith repositioning maneuvers or balance training), pharmacotherapy, surgery, and psychotherapy. Since there are very few state-of-the-art RCTs, the treatment of vestibular disorders is so far not standardized and various methods are applied with heterogeneous efficacy.
Author's Reply to Zhou et al: Comment on "Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population".
CNS Drugs
January 2025
Department of Otolaryngology, Teikyo University Hospital, Mizonokuchi, 5-1-1 Futako, Takatsu-ku, Kawasaki, Kanagawa, 213-8507, Japan.